Oppenheimer Maintains Outperform Rating on Mindray Medical
According to Oppenheimer, Mindray Medical Int'l (NYSE: MR) Outperform rating is maintained.
Oppenheimer said that it sees resilience in China's medical device industry and little correlation of ShenZhen medical device exports with China's total exports. “We believe besides top-line growth, margins and 2012 guidance will be key factors affecting near-term stock price. Maintain Outperform.”
Mindray Medical Int'l closed yesterday at $25.48.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.